Home › Agent Hub › Agent Tools › Part D coverage by drug › Invokana
Agent Tools
Invokana is a brand of canagliflozin. What agents check before quoting it: how many 2026 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.
In 2026, 724 of 5,496 Medicare Part D and Medicare Advantage drug plans (13.2%) list Invokana on their formulary, across 19 of 328 formularies. The most common placement is tier 4 (477 plans, 65.9% of those covering it). 0 of the covering plans require prior authorization (0%), 0 step therapy and 724 a quantity limit.
125 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $50; 599 charge coinsurance instead — median 29% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,100 in 2026, covered drugs cost $0 for the rest of the year.
2025: 1,448 of 5,631 plans covered it (25.7%); 2026: 724 of 5,496 (13.2%).
Of 4,368 plans offered in both years, 63 added it to the formulary and 594 dropped it.
Among plans covering it both years, 11 moved it to a higher tier and 35 to a lower one; 0 added prior authorization and 0 removed it.
Medicare Part D paid for 494,940 30-day fills of Invokana in 2024 for about 55,968 enrollees, at an average total cost of $548.59 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).
Price Invokana and the rest of a client's list on every plan in their county.
Estimate Invokana costs by plan
Free tools for licensed insurance agents. Data from CMS public files; verify with plan documents before advising a client.
Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 09/16/2026). CMS formulary data.